# OnCo record rondo-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/rondo-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "rondo-therapeutics" ;
  schema:name "Rondo Therapeutics"@en ;
  schema:description "Rondo Therapeutics makes two-armed antibodies that grab a tumour protein with one arm and give T cells an extra activation signal with the other, so the immune system attacks solid tumours. Its first drug, RNDO-564, is in an early trial for bladder cancer and other tumours that carry Nectin-4."@en ;
  schema:url <https://onco.cc/companies/rondo-therapeutics/>, <https://www.rondotx.com/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://www.rondotx.com/>, <https://www.businesswire.com/news/home/20241204127623/en/Rondo-Therapeutics-Announces-Collaboration-with-Lilly-to-Develop-Novel-CD28-Bispecific-Antibodies-for-Solid-Tumors>, <https://clinicaltrials.gov/study/NCT07218003> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/urothelial/>, <https://onco.cc/cancers/head-and-neck/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/cervical/>, <https://onco.cc/cancers/tnbc/> ;
  onco:sections <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/bispecific-antibody/> ;
  onco:targets <https://onco.cc/targets/cd28/>, <https://onco.cc/targets/nectin4/> ;
  onco:trials <https://onco.cc/trials/nct07218003/> .